Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction

Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness

Published in: Evidence Report/Technology Assessment: no. 82 (Prepared by the Southern California/RAND Evidence-based Practice Center under contract No. 290-97-0001). AHRQ Publication No. 03-E045. Agency for Healthcare Research and Quality, Rockville, MD. July 2003

Posted on on January 01, 2003

by Paul G. Shekelle, Sally C. Morton, Sidney W. Atkinson, Marika Booth, Wenli Tu, Paul Heidenreich, Matthew Gubens, Margaret A. Maglione, Lara Hilton, Elizabeth Roth, et al.

Read More

Access further information on this document at

This article was published outside of RAND. The full text of the article can be found at the link above.

Heart failure (HF) is associated with substantial morbidity and mortality; it is a primary or secondary cause of death for approximately 250,000 people per year in the United States. According to the 2002 Heart and Stroke Statistical Update (, HF was the first-listed diagnosis for 962,000 hospitalizations in 1999, and it is the most common diagnosis among hospital patients age 65 and older. In fact, 20 percent of all hospitalizations in this age group carry a primary or secondary diagnosis of HF. Over 3 million outpatient office visits each year are related to this illness. In 1998 alone, the estimated annual direct cost due to HF was $18.8 billion. A series of studies has established that angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-adrenergic blocking agents (beta-blockers) provide life-saving benefits in patients with HF and left ventricular systolic dysfunction. However, most of the patients enrolled in such studies have been white males. Thus, a clinical question that is repeatedly asked is whether the mortality benefit reported in these clinical trials is also achieved for particular subpopulations, such as women, people of other races, and patients with various comorbidities such as diabetes mellitus or renal insufficiency. Since few of the randomized trials enrolled enough women, blacks, or patients with comorbidities to have sufficient statistical power to support conclusions based on subgroup analysis, this question is appropriate for meta-analysis. In addition, because the clinical trial data support a mortality benefit for patients with asymptomatic left ventricular dysfunction, it is natural to question both the cost-effectiveness of such treatment and that of screening asymptomatic patients for left ventricular dysfunction. These clinical and policy questions form the basis for this report.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.